Abbott Korea launches XIENCE V stent

Published: 2008-05-15 06:56:00

Updated: 2008-05-15 06:56:00

Abbott Korea says it has launched its XIENCE V Everolimus Eluting Coronary Stent System, offering physicians a smaller stent based upon the proven efficacy, positive safety results and excellent deliverability of XIENCE V, after getting reimbursement approval from the Health Insurance Review Agency.

Superiority for XIENCE V compared to TAXUS paclitaxel eluting coronary stent system in the pr...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.